Mojtaba Panjehpour

Mojtaba Panjehpour

Auto-generated profile, based on publicly available information

Mojtaba Panjehpour

Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2015 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
MEMaryam Esfahani
Maryam Esfahani
NANegar Ataei
Negar Ataei
MPMojtaba Panjehpour
Mojtaba Panjehpour
Biomarkers for Evaluation of Prostate Cancer Prognosis Biomarkers;prostate cancer;PSA;prediction of prognosis; Prostate cancer, with a lifetime prevalence of one in six men, is the second cause of malignancy-related death and the most prevalent cancer in men in many countries. Nowadays, prostate cancer diagnosis is often based on the use of biomarkers, especially prostate-specific antigen (PSA) which can result in enhanced detection at earlier stage and decreasing in the number of metastatic patients. However, because of the low specificity of PSA, unnecessary biopsies and mistaken diagnoses frequently occur. Prostate cancer has various features so prognosis following diagnosis is greatly variable. There is a requirement for new prognostic biomarkers, particularly to differentiate between inactive and aggressive forms of disease, to improve clinical management of prostate cancer. Research continues into finding additional markers that may allow this goal to be attained. We here selected a group of candidate biomarkers including PSA, PSA velocity, percentage free PSA, $TGF{\beta}1$, AMACR, chromogranin A, IL-6, IGFBPs, PSCA, biomarkers related to cell cycle regulation, apoptosis, PTEN, androgen receptor, cellular adhesion and angiogenesis, and also prognostic biomarkers with Genomic tests for discussion. This provides an outline of biomarkers that are presently of prognostic interest in prostate cancer investigation.

18 October 2017 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
AGAhmad Ghasemi
Ahmad Ghasemi
SHSeyed Isaac Hashemy
Seyed Isaac Hashemy
MAMahmoud Aghaei
Mahmoud Aghaei
MPMojtaba Panjehpour
Mojtaba Panjehpour

1 April 2017 in Cellular Signalling
Verified
Journal Article
Closed access
AGAhmad Ghasemi
Ahmad Ghasemi
SHSeyed Isaac Hashemy
Seyed Isaac Hashemy
MAMahmoud Aghaei
Mahmoud Aghaei
MPMojtaba Panjehpour
Mojtaba Panjehpour

1 December 2007 in Oncology Research
Verified
Journal Article
Closed access
MPMojtaba Panjehpour
Mojtaba Panjehpour
FKFatemeh Karami-Tehrani
Fatemeh Karami-Tehrani
Adenosine modulates the proliferation, survival, and apoptosis of many different cell types. The present study was performed to investigate the role of adenosine receptors in the human breast cancer cell lines MCF-7 and MDA-MB468. The biological effects of adenosine on the cells were analyzed by adenylyl cyclase and cell viability assay as well as RT-PCR of adenosine receptors. RT-PCR results show the expression of the transcript of all adenosine receptors in both cell lines. By using adenosine and selective adenosine receptor agonists or antagonists, we found that A3 stimulation reduced cell viability, which was abolished by pretreatment with A3 receptor antagonist. Moreover, we demonstrated that adenosine (natural agonist) triggers a cytotoxic signal via A3 receptor activation that was not seen for other subclasses of adenosine receptors. Intracellular cAMP concentration was changed significantly only for A3 and A2B receptor-selective agonists, which indicates the functional form of these receptors on the cell surface. In conclusion, our findings revealed the role of adenosine receptors in breast cancer cell lines on growth modulation role of A3 and functional form of A2B, although its involvement in cell growth modulation was not seen. Theses findings as well as data by others may provide a possible application of adenosine receptor agonists/antagonists in breast malignancies.

20 February 2015 in The Prostate
Verified
Journal Article
Closed access
PDF file
SMSamira Mousavi
Samira Mousavi
MPMojtaba Panjehpour
Mojtaba Panjehpour
MIMohammad Hossein Izadpanahi
Mohammad Hossein Izadpanahi
MAMahmoud Aghaei
Mahmoud Aghaei